New research suggests a link between some weight loss drugs and potentially blinding eye diseases. That risk is especially high for older adults. A recent study found that older adults with diabetes ...

All 50 states, D.C., and four U.S. territories signed off on the multi-billion dollar settlement proposal with OxyContin ...

NVO jumps nearly 6% in a week on amycretin pipeline boost and hedge fund interest, but competition looms large.

Pennsylvania Governor Josh Shapiro's office has said it is looking to change eligibility for weight loss drugs as part of its 2025-26 budget plans.

Wondering how to feel about Ozempic? These unexpected questions help reveal what may really be driving your reaction and how ...

Novo Nordisk (NYSE: NVO) has permanently forfeited Canadian patent protection for semaglutide—the blockbuster active ...

LEXX Lexaria Bioscience Corp. (NASDAQ:LEXX) announced that it had completed its GLP-1-H25-5 study last week and reported ...

McDonald’s faces falling visits and shrinking demand as GLP-1 drugs and price fatigue reshape consumer habits.

A MUM-of-two who used to cancel nights out because she felt like “the fat one” has lost two stone in two months by using Mounjaro. Sarah Hill, 32, from Glasgow, is among the estimated 1.5 million ...

Find out if Novo's GLP-1 patent expiring in Canada is a mistake or a calculated move. Did the firm lose exclusivity over a ...

We have recently begun acquiring a new position in Novo Nordisk. Click here for our investment thesis on NVO stock.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.